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Abstract
Salmonella strains have been actively studied as live carriers of heterologous antigens for 
a possible vaccine application. Especially, Salmonella Typhimurium, a facultative anaer-
obe, has been adapted as an antitumor agent capable of preferentially proliferating 
within tumors and inhibiting their growth. To enhance the cancer therapeutic efficacy 
of S. Typhimurium, combinations of gene-directed protein or microRNA therapies and 
auxotrophic strains of S. Typhimurium have been generated by genetic engineering. Until 
now, the idea of using bacteria including Salmonella in the treatments of cancer and other 
diseases has been considered a novel approach. Here, we describe this application based 
on Salmonella engineering for treatments of cancer or atopic dermatitis.
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1. Introduction
Salmonella strains have been used to prepare attenuated vaccines. These bacteria invade epi-
thelial cells and secrete the internal protein of bacteria. Thus, Salmonella strains have been 
adapted as carriers for delivery of a recombinant antigen, therapeutic protein, or functional 
plasmid. After invading the intestinal epithelium, a modified Salmonella strain survives and 
replicates within antigen-presenting cells such as macrophages, mast cells, and dendritic cells.
Salmonella induces strong mucosal and cell-mediated immune responses against recombinant 
antigens [1, 2]. Recombinant proteins expressed by S. Typhimurium can be secreted and rec-
ognized by host immune cells with or without lysis of the bacteria. However, Salmonella rep-
lication within a membrane-bound vacuole inhibits processing of a recombinant protein by 
antigen-presenting cells [3]. Therefore, in a genetically modified Salmonella strain, a method 
for effective delivery of a recombinant protein carried by bacteria into the host is needed for 
the development of an effective therapeutic strain.
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Salmonella strains secrete recombinant proteins and introduce a heterologous protein into the 
extracellular environment. Salmonella strains use a type III secretion system (T3SS) to deliver 
cytoplasmic effector proteins into host cells [4]. In most T3SS-secreted proteins, Salmonella uses 
the N-terminal region for the signal for secretion of the target protein [5]. When several anti-
genic peptides are fused to the secretion domain of effector protein SopE of S. Typhimurium 
or YopE of Yersinia enterocolitica, the recombinant proteins are exported in a T3SS-dependent 
manner, resulting in activation of an immune response in mouse models [6, 7]. S. Typhimurium 
possesses two T3SSes encoded by Salmonella pathogenicity islands (SPIs) 1 and 2; SPI-1 is 
required for invasion of non-phagocytic epithelial cells, and SPI-2 for replication and survival 
in macrophages [4].
Salmonella has also been exploited as an antitumor agent that is capable of preferentially amplify-
ing within a tumor and inhibiting its growth [8, 9]. In an effort to enhance therapeutic efficacy, 
this approach has been combined with a gene-directed enzyme/prodrug therapy [10]. For exam-
ple, auxotrophic S. Typhimurium expressing prodrug-converting enzymes has been generated 
by transformation with a prokaryotic expression vector encoding herpes simplex virus thymi-
dine kinase [11] or by chromosomal insertion of the Escherichia coli cytosine deaminase gene [12]. 
Salmonella has also been engineered for the transfer of prokaryotic and eukaryotic expression 
plasmids into host cells [13]. Oral administration of genetically modified Salmonella carrying a 
eukaryotic expression plasmid encoding interferon-gamma (IFN-γ) restores the production of 
this cytokine in the macrophages in mice [14]. When delivered orally to mice, S. Typhimurium car-
rying eukaryotic expression vectors encoding cytokines (i.e., interleukin-12 or GM-CSF) increases 
cytokine concentrations and exerts antitumor effects [15]. Thus, it should be feasible to use 
Salmonella strains transformed with eukaryotic expression vectors to deliver various effector mol-
ecules to cancer cells or skin inflammation sites, with the goal of enhancing therapeutic activity.
2. Medical application of Salmonella engineering
2.1. Salmonella strains are used as a carrier for delivery of a foreign protein or 
genetic material
Salmonella strains are considered good candidates as a vector for delivery of a foreign protein 
and/or plasmid(s). Attenuated S. Typhimurium strains are easy and cheap vector microbes to 
produce an antigen in comparison with any other synthetic protein delivery system and have 
been evaluated as vehicles for delivery of a plasmid expressing a heterologous antigen(s) to 
the host. Not only cytoplasmic expression of a recombinant protein in S. Typhimurium but 
also secretion or surface display of the target protein is a promising strategy for enhancing 
vaccine effects by improving recombinant antigen presentation in antigen-presenting cells. In 
one study, researchers used the T3SS signal from SipB, which possesses the domains for its 
secretion and outer membrane localization.
Many Gram-negative bacteria have a T3SS to deliver effector proteins into host cells, and the 
secretion signals of T3SS substrates have been used as carrier molecules for the delivery of 
foreign antigens or therapeutic molecules.
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In an animal experiment, oral administration of attenuated S. Typhimurium bearing therapeu-
tic plasmids showed that this strain secretes and surface-displays the SipB tetanus toxin and 
induces a strong antigen-specific immune response in mice.
Oral vaccination of mice with attenuated S. Typhimurium carrying T3SS-based delivery plas-
mids may increase the recombinant protein presentation in antigen-presenting cells, resulting 
in induction of recombinant protein-specific immune responses in mice. These findings sug-
gest that the N-terminal domain of SipB can serve as a signal sequence for the surface display 
and secretion of heterologous proteins.
However, successful T3SS-mediated antigen delivery is restricted by several factors, includ-
ing the size, folding, stability, and structure of a recombinant protein.
When a highly virulent Salmonella strain (S. Typhimurium UK-1) is transformed with a cytokine 
(IL-12)-expressing plasmid, this live, wild-type pathogen has been shown to work as a vaccine 
strain without any other biological or genetic attenuating processes.
Wild-type pathogenic S. Typhimurium UK-1 carrying an IL-12-expressing plasmid induces 
protection against a lethal dose of normal wild-type Salmonella [16]. These results also revealed 
that a wild-type Salmonella strain bearing a plasmid for secretion of IL-12 may be considered 
an alternative approach to the development of intracellular bacterial vaccines, without the 
inconvenience of time-consuming attenuation procedures.
2.2. Engineered Salmonella has therapeutic effects on cancer
In the field of anticancer therapeutic agents, biological modalities such as cell therapy, gene 
therapy, and antibody-related immunotherapy have been developed as possible candidates 
for cancer therapeutics. In addition to these new candidates, bacterial therapy is believed to 
be a promising technology of tumor treatments and tumor vaccines. This kind of bacterial 
therapy is safer, less expensive, and more versatile than other biological cancer treatments. 
These therapeutic bacteria could be produced cheaply. Moreover, Salmonella is thought to be 
a good anticancer therapeutic agent and has shown tumor-targeting properties and tumor-
suppressing effects in some studies [17]. Tumor-targeted Salmonella has a tumor accumula-
tion ratio greater than 1000:1 as compared to healthy tissues [9], and many research groups 
have used Salmonella strains for the development of anticancer agents [18]. In one study, 
a genetically engineered strain of S. Typhimurium expressing TNF-α was tested as a mela-
noma-suppressing agent. This Salmonella was attenuated for safety toward healthy cells and 
was specifically localized to and invaded various melanoma cells while bombarding them 
with tumor necrosis factor (TNF) proteins to induce tumor cell apoptosis. VEGF, p53, p19, 
IFNs, and other cytokines have been tested as tumor-suppressor proteins in Salmonella vec-
tor systems. Although systemically administered cytokines have short half-life and severe 
side effects after direct administration, cytokines are often used for regulation of the immune 
system and for tumor cell lysis [19]. For Salmonella cancer therapy, researchers engineered 
Salmonella expressing the TNF-α protein—a potent antitumor molecule that normally has 
limitations because of its side effects—to reduce the adverse effects via tumor-specific local 
immunotherapy [20].
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In our test of Salmonella-based TNF-α therapy, the targeted recombinant TNF-α from bacte-
ria did not induce histological changes in various tissues and cytokine upregulation such as 
severe inflammations after local administration of recombinant Salmonella. Some research-
ers reported that cytokine-expressing S. Typhimurium could act as a good biological antican-
cer agent without the cytotoxicity of high-dose cytokine administration. The production of 
genetically modified Salmonella would be convenient and easy, with a low cost and a short 
manufacture period; such biological anticancer agents are expected to have synergistic effects 
(bacterial cytotoxicity and immunostimulation by anticancer cytokines). In addition, bac-
teria can function as gene delivery shuttles for transporting recombinant gene vectors [11]. 
According to the latest studies, recombinant Salmonella produces 100 pg of TNF-α per 109 
cells. TNF-α is not secreted into the normal environment, but is released into tumor cells 
after bacterial invasion of these cells. Accordingly, genetically modified Salmonella carrying a 
cytokine expression vector (e.g., S. Typhimurium expressing TNF-α) is known to express cyto-
kines in melanoma cells and to suppress tumor growth in mice with melanoma, colon cancer, 
or breast cancer. Therefore, S. Typhimurium expressing TNF-α may serve as a therapeutic 
agent against various tumors and as an adjuvant to existing cancer therapies such as chemo-
therapy, radiotherapy, and immunotherapy. These findings suggest that Salmonella carrying 
a cytokine expression vector can act as a new, safe, and efficient anticancer agent. In particu-
lar, to determine the cytotoxic effects of genetically modified Salmonella, B16F10 melanoma 
cells were treated with S. Typhimurium expressing TNF-α. The S. Typhimurium expressing 
TNF-α invaded tumor cells at a higher invasion rate (50%) than did a naïve Salmonella strain 
and lysed the melanoma cells [21]. These results indicate that genetically modified Salmonella 
expressing TNF-α specifically lyses B16F10 melanoma cells in contrast to naïve Salmonella 
strains (Figure 1a) and that the engineered S. Typhimurium expressing TNF-α induces caspase 
activation for tumor cell lysis and inhibited tumor growth in tumor-bearing mice (Figure 1b).
Additionally, a Salmonella-based cancer therapy may not be compatible with antibiotics like 
gentamicin, and host immune responses and environments conducive to bacterial killing are 
Figure 1. Construction and effects of the recombinant Salmonella Typhimurium containing TNF-α.
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likely to be disadvantageous for Salmonella-based cancer treatment. In some studies, researchers 
investigated the impact of antibiotics on a Salmonella-based cancer therapy. Tumor-bearing mice 
were treated with Salmonella expressing TNF-α and an antibiotic (gentamicin). Another group 
of mice was vaccinated with attenuated Salmonella, received a transplant of melanoma cells, and 
was then examined for the tumor inhibitory effect of Salmonella expressing TNF-α. In an in vivo 
assay, gentamicin did not interfere with Salmonella-mediated therapy of tumor cells (Figure 2a). 
In tumor-bearing mice, treatment with Salmonella and cisplatin also inhibited tumor growth 
(Figure 2b). In mice that were vaccinated with dendritic cells, host immune responses did 
not suppress tumor inhibition by Salmonella expressing TNF-α (Figure 2c). In treatment with 
Salmonella and radiation, Salmonella expressing TNF-α also inhibited tumor growth (Figure 2d). 
These results showed that the antitumor activity of subcutaneous treatment with Salmonella 
expressing TNF-α is not suppressed by antibiotics and host immune responses in mice.
Other studies were conducted on a vaccine based on recombinant Salmonella expressing 
human papilloma virus antigens [22]. This recombinant Salmonella was constructed from 
Salmonella enterica serovar Typhimurium expressing a fusion protein consisting of the SipB 
protein from Salmonella and the HPV16 E7 protein derived from human papillomavirus 
for tumor-suppressing effects. The genetically modified Salmonella expressing SipB-E7 was 
tested in a cervical cancer model. In cervical cancer TC-1-bearing mice, Salmonella expressing 
SipB-E7 induced cytotoxicity and slowed tumor growth after oral inoculation. Moreover, in the 
mouse model of cervical cancer, orally administered Salmonella expressing SipB-E7 induced 
cytokines IFN-γ and TNF-α and prolonged survival compared with the control group (naïve 
Salmonella or PBS-treated groups). These results revealed that Salmonella expressing fusion 
protein SipB160-E7 may be a candidate cancer therapeutic agent. Yoon et al. took advantage 
of a genetically engineered Salmonella strain as a candidate tumoricidal modality; to enhance 
tumor-suppressing effects, S. Typhimurium was designed to carry eukaryotic expression 
Figure 2. Tumour inhibition of S. Typhimurium containing TNF-α with antibiotics or vaccine or cisplatin.
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plasmid expressing the Flt3 ligand (Flt3L) [23]. Salmonella carrying the Flt3L expression vec-
tor exerted antitumor effects against B16F10 melanoma cells in vitro. When the engineered 
Salmonella was injected locally into the tumor region, S. Typhimurium with the Flt3L expres-
sion vector inhibited tumor growth more effectively relative to control groups. Nonetheless, 
in the mice cured of melanoma after treatment with recombinant Salmonella, there was no 
induction of tumor immunity mediated by memory antitumor lymphocytes because there 
was no protective responses against a tumor rechallenge.
Compared to radiation alone, a combination therapy, Salmonella with γ-radiation, confers radio-
sensitization onto cancer cells by inducing apoptotic cell death [24]. Salmonella infection induces 
apoptosis via caspase 3 and Bcl2 in tumor cells. In addition, tumor growth is suppressed by this 
combined therapy pointing to possible new versions of radiation therapy against melanoma. 
Overall, cancer radiation therapy is significantly improved by the use of bacteria. For this rea-
son, our findings indicate that bacteria may help to increase effectiveness of cancer radiation 
therapy in the future.
2.3. Engineered Salmonella induced therapeutic effects on atopic dermatitis
Salmonella-based therapy has been examined as a therapeutic agent for allergic diseases. 
Excessive Th2-biased immune responses are related to the pathogenesis of allergic diseases. 
Macrophage-derived chemokine (MDC) is directly related to Th2-associated atopic dermati-
tis, and MDC concentration is significantly elevated in the serum of patients. MDC has been 
studied as a marker of severity of atopic dermatitis. Yoon et al. tested genetically modified 
Salmonella as a gene therapy tool to treat atopic dermatitis with bacteria expressing specific 
microRNA [25]. To suppress the MDC gene for atopic dermatitis therapy, a S. Typhimurium 
strain was constructed that carries a plasmid expressing MDC microRNA. The engineered 
Salmonella strain bearing the microRNA-expressing plasmid (ST-miR-MDC) was used for an 
in vitro knockdown of MDC in human mast cells [26]. ST-miR-MDC was shown to signifi-
cantly downregulate the MDC gene in activated human mast cells in vitro. In an atopic-like 
animal model, strain ST-miR-MDC downregulated IL-4 and IgE expression and upregulated 
IFN-γ. Strain ST-miR-MDC also suppressed Th17 in the atopic-like animal model (Figure 3).
In addition, orally administered strain ST-miR-MDC induced skin regeneration and hair 
regrowth in atopic-like mice, but control mice did not show these effects (Figure 4a). Pruritus 
Figure 3. Construction of the recombinant Salmonella Typhimurium expressing miRNA-MDC.
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is one of the major symptoms of atopic dermatitis, and the ST-miR-MDC strain inhibited the 
scratching behavior of mice. The total scratching counts in the ST-miRCCL22-treated group 
were significantly lower than those among the mice treated with PBS or ST-miR-control 
(Figure 4b). This strain induced histological changes in the skin tissues of atopic-like mice after 
oral administration of the engineered Salmonella. Strain ST-miR-MDC reduced skin inflamma-
tion reactions and reduced cytokine IL-4, MDC, and IgE on mouse blood (Figure 4c).
These results indicate that Salmonella combined with a targeted microRNA delivery sys-
tem may be a good candidate for the development of a therapeutic agent against atopic 
dermatitis.
3. Conclusions
To date, the idea of using bacteria, including Salmonella therapy, has been considered a novel 
approach. S. Typhimurium bearing a cytokine-expressing plasmid exerts an antitumor effect 
on melanoma or anti-inflammatory effects in an atopic-like mouse model.
The engineered Salmonella has been designed to target cancer cells, promote a tumor-suppressive 
environment, and increase the efficacy of existing cancer treatments, including chemotherapy, 
radiotherapy, and cell therapy.
Especially, Salmonella expressing microRNA has been used in vivo to knockdown a target 
gene and shows modulation of immune responses in a mouse disease model.
These results suggest that genetic engineering of S. Typhimurium may be an efficient method 
of delivery of cytokines or microRNA for therapeutic purposes.
Figure 4. Improvement of the symptoms of atopic dermatitis by oral administration of S. Typhimurium miR-MDC in mice.
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